Bristol-Myers Squibb Company and Samsung BioLogics have entered into a 10-year biotech partnering agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.
Financial terms for the biotech partnering agreement were not disclosed.
Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.
For further deal information visit Current Agreements (subscription required)
Read: more on BMS company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Bristol-Myers Squibb
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity